Related Experiment Video
Updated: Feb 4, 2026

Robotic Ablation of Atrial Fibrillation
Published on: May 29, 2015
[How to manage anticoagulation in atrial fibrillation ablation]
1Unité de rythmologie, GHI Le Raincy-Montfermeil, 10, rue du Général-Leclerc, 93370 Montfermeil, France.
Abstract:
There are many randomized trials evaluating non-vitamin K oral anticoagulants (NOAC) in patients with atrial fibrillation ablation. VENTURE AF, RE-CIRCUIT, and recently AXAFA have evaluated the three main NOACs in this indication. Other studies such as ABRIDGE J and AEIOU complemented these results. The management of the anticoagulation in these patients is one of the subjects of the European Society of Cardiology guidelines, as well, as, the EHRA guide recently released. The purpose of this article is to summarize published studies and guidelines.
Insights
Non-vitamin K oral anticoagulants (NOACs) are evaluated in atrial fibrillation ablation trials. This review summarizes key studies and guidelines for anticoagulation management in these patients.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Atrial fibrillation ablation requires careful anticoagulation management.
- Non-vitamin K oral anticoagulants (NOACs) are increasingly studied for this indication.
Purpose of the Study:
- To summarize randomized trials evaluating NOACs in atrial fibrillation ablation.
- To review current European Society of Cardiology and EHRA guidelines on anticoagulation for ablation patients.
Main Methods:
- Review of published randomized controlled trials (VENTURE AF, RE-CIRCUIT, AXAFA).
- Inclusion of data from complementary studies (ABRIDGE J, AEIOU).
- Analysis of European Society of Cardiology and European Heart Rhythm Association guidelines.
Main Results:
- Multiple trials have assessed NOAC efficacy and safety in atrial fibrillation ablation.
- Guidelines provide recommendations for anticoagulation management in this patient group.
Conclusions:
- Evidence from trials supports the use of NOACs in atrial fibrillation ablation.
- Guidelines offer a framework for optimal anticoagulation strategies.
More Related Videos
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid Fibrils
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Fibril-associated Collagen
For example, the type II collagen fibrils in cartilage have covalently bound type IX fibril-associated collagens at regular intervals. Other types of fibril-associated collagens are...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Tonsillitis II: Management

